Hemanext is driving a new era in transfusion medicine by advancing oxygen-controlled blood storage. Through ongoing scientific research, partnerships with leading blood establishments, and active participation in international conferences, we continue to share evidence and insights that help shape the future of blood quality and patient care. Stay up to date with Hemanext’s latest developments.
Hemanext Expands Commercial Footprint Through Strategic Partnership with OneBlood
We are proud to announce a strategic partnership with OneBlood, one of the nation’s largest independent blood centers.
This is a significant milestone in Hemanext’s commercial expansion, accelerating adoption of Hemanext ONE® and expanding patient access to oxygen-controlled red blood cells across the United States.
European Multicenter Validation Confirms Quality of Oxygen-controlled RBCs
Independent, multicenter data demonstrate consistent performance of oxygen-controlled red blood cells across Europe.
Results from a six-center European validation study (Agostini et al., Transfusion, 2025) confirm that red blood cells processed using the Hemanext ONE System consistently meet regulatory and blood center quality standards after 42 days of storage. The findings demonstrate reproducibility across Italy, Germany, Norway, and Switzerland and reinforce the scalability of oxygen-controlled storage.
Better Red Blood Cells — With Dedicated U.S. Reimbursement
CMS recognition enables hopitals to adopt oxygen-controlled RBCs without financial trade-offs.
The U.S. Centers for Medicare & Medicaid Services have assigned a unique HCPCS code for oxygen-controlled red blood cells, recognizing their innovation and enabling differentiated reimbursement within existing workflows.
Hemanext actively participates in major scientific and industry meetings to share data and engage with the transfusion community.
